September 9, 2025Open Access

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Cho et al. (Tue,) studied this question.

synapsesocial.com/papers/69d76c03ef4aa71f97f314b5 https://doi.org/https://doi.org/10.1016/j.jtho.2025.07.117

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.2023 · 23 citations
2Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study2024 · 15 citations
3A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors2016 · 283 citations
4Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach2022 · 31 citations
5Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer2017 · 537 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo